Clinical trial · Interventional
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated early for business reasons.
Summary
Brief summary (as posted)
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Large B Cell Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ALLO-501A | Genetic | — | UNRESOLVED |
| ALLO-647 | Biological | Alemtuzumab | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Fludarabine | Drug | Fludarabine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Lymphodepletion with ALLO-647, fludarabine, and cyclophosphamide
- description
- ALLO-501A CAR T cells infused following lymphodepletion
- interventionNames
- Biological: ALLO-647
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Genetic: ALLO-501A
- type
- EXPERIMENTAL
- label
- Lymphodepletion with fludarabine and cyclophosphamide
- description
- ALLO-501A CAR T cells infused following lymphodepletion
- interventionNames
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Genetic: ALLO-501A
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse * Relapsed or refractory disease after at least 2 lines of chemotherapy * ECOG performance status 0 or 1 * Absence of significant donor (product)-specific anti-HLA antibodies (DSA) * Adequate hematological, renal and liver function Exclusion Criteria: * Active central nervous system involvement by malignancy * Autologous or allogeneic HSCT within last 6 months prior to lymphodepletion * Hypocellular bone marrow for age
References
Publications (0)
Data not yet available